Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2013


SMi - Cancer Vaccines

18 Sep 2013 - 19 Sep 2013 - London, UK



Bookmark and Share


SMi proudly presents the 2nd annual conference on Cancer Vaccines taking place on 18th and 19th September, London. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.

As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.

Cancer Vaccine 2013 will examine not only current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.

Benefits of Attending:

Explore innovative and novel strategies, approaches, and vaccines within the field.

Discover future trends, the direction of the field, and combination strategies in both preclinical and clinical situations.

Evaluate the regulatory environment and the subsequent impact on cancer vaccine development.

Consider current trial data, clinical developments, and successful therapeutic vaccines

Learn from successes, failures, and challenges from experts in the field, and apply to optimise vaccine development

Speakers include:

Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA

Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland

Martin Glennie, Professor of Immunochemistry, University Of Southampton

Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research

Rose-Ann Padua, Research Director, INSERM

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

REGISTER ONLINE AT www.smi-online.co.uk/goto/2013cancervaccinesevent47.asp

For further information, contact Fateja Begum on Tel: +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk



Further information
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!